Amol Akhade: Survey for advanced biliary tract cancer treatment
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“For advanced BTC, with both durva and Pembro Plus chemotherapy, showing similar magnitude of benifit (median OS 12.9 vs 12.7 months respectively) and similar toxicity, which one will you prefer and why, as 1st line option for patients who is fit for both and has access to both?
Do Participate in this survey on X and let me know.”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplants.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023